INDIANAPOLIS, USA – Indiana University School of Medicine researchers have made a significant breakthrough in developing a new gene therapy approach that restores full-length dystrophin protein, which could lead to new treatments for people with Duchenne muscular dystrophy (DMD). The study, recently published in Nature Communications, demonstrates the effectiveness of their novel gene therapy technology in improving muscle tissue and overall strength in mice models with Duchenne muscular dystrophy. Duchenne muscular dystrophy is...
Latest News
WASHINGTON – A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one’s risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general...
WASHINGTON – Individuals living with severe sickle cell disease (SCD) are highly interested in new, potentially curative gene therapy treatments and are willing to accept associated risks for a chance at a cure, according to a study published today in Blood Advances. SCD is an inherited red blood cell disorder...
Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand...
FRANKFURT, Germany – Wanderlust and climate change mean that viruses transmitted by mosquitoes are increasingly spreading across Europe. The class of flaviviruses, which comprises the dengue, Zika, West Nile and yellow fever viruses, cause serious neurological diseases for which only insufficiently effective vaccines and no specific treatment options currently exist....
BERLIN, Germany – Infection with the stomach bacterium Helicobacter pylori could increase the risk of developing Alzheimer’s disease: In people over the age of 50, the risk following a symptomatic infection can be an average of 11 percent higher, and even more about ten years after the infection, at 24...
NEWTON, Mass. — Inflammasome Therapeutics, a clinical-stage, private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a Phase 1 study of one of the company’s novel compounds in the treatment of diabetic macular edema...
Jena, Germany – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive data from the third cohort of patients in the Phase IIa open-label study with vilobelimab in Pyoderma Gangrenosum (PG). “We are happy to see more patients responding with the...
Jena, Germany – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the achievement of target enrollment of the Phase IIa open label study of vilobelimab in patients with Pyoderma Gangrenosum (PG). Dr. Korinna Pilz, Global Head of Clinical Research and...
Jena, Germany – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa (HS) patients with active draining tunnels. The new primary endpoint, called modified HiSCR (Hidradenitis Suppurativa Clinical Response),...